Ercanetide

Ercanetide
Clinical data
Other names	Cyclo(L-glycyl-L-2-allylproline)
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (8aR)-8a-Prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione;
CAS Number	847952-38-9 ;
PubChem CID	11735696 ;
DrugBank	DB15601 ;
ChemSpider	9910403 ;
UNII	2T1HU6069S ;
ChEMBL	ChEMBL4802144 ;
Chemical and physical data
Formula	C10H14N2O2
Molar mass	194.234 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C=CC[C@@]12CCCN1C(=O)CNC2=O;
	InChI InChI=1S/C10H14N2O2/c1-2-4-10-5-3-6-12(10)8(13)7-11-9(10)14/h2H,1,3-7H2,(H,11,14)/t10-/m0/s1; Key:WVKCGUOWPZAROG-JTQLQIEISA-N;

Last updated August 12, 2025

Ercanetide (INN Tooltip International Nonproprietary Name;^[1] developmental code name NNZ-2591) is a synthetic analog of cyclic glycine-proline (cGP) and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome,^[2]^[3] and Prader-Willi syndrome.^[4]

References

↑ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf ^{[ bare URL PDF ]}
↑ Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs. 30 (7): 709–720. doi: 10.1080/13543784.2021.1939674 . PMID 34112038.
↑ Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome" . Current Opinion in Psychiatry. 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. PMID 33395098. S2CID 230663523.
↑ "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". clinicaltrials.gov. Retrieved 6 December 2023.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] ttps://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf ^{[ bare URL PDF ]}

[2] Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs. 30 (7): 709–720. doi: 10.1080/13543784.2021.1939674 . PMID 34112038.

[3] Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome" . Current Opinion in Psychiatry. 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. PMID 33395098. S2CID 230663523.

[4] "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". clinicaltrials.gov. Retrieved 6 December 2023.

[1]

[2]

[3]

[4]

Ercanetide

See also

References